Treatment and prevention of Lyme disease, with emphasis on antimicrobial therapy for neuroborreliosis and vaccination

Seminars in Neurology

Volumn 17, Issue 1, 1997, Pages 45-52

  Wormser, Gary P ^a,b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

antibiotic; antimicrobial; blood brain barrier; Lyme disease; neuroborreliosis; Vaccine

Indexed keywords

AMOXICILLIN; BACTERIAL VACCINE; CEFOTAXIME; CEFTRIAXONE; DOXYCYCLINE; FLAGELLIN; OUTER MEMBRANE PROTEIN; PENICILLIN G;

ANTIBIOTIC THERAPY; ARTICLE; BLOOD BRAIN BARRIER; BORRELIA BURGDORFERI; CLINICAL FEATURE; DISEASE TRANSMISSION; FACIAL NERVE PARALYSIS; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; LYME DISEASE; MENINGITIS; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADICULOPATHY; VACCINATION; VACCINE PRODUCTION;

EID: 0030962165     PISSN: 02718235     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1040912     Document Type: Article

References (91)

1. Steere AC. Lyme disease. N Engl J Med 1989;321:586-96
2. Garin CH, Bujadoux C. Paralysie par les tiques. J Med Lyon 1922;71:765-7
3. Garcia-Monco JC, Benach JL. Lyme neuroborreliosis. Ann Neurol 1995;37:691-702
4. Halperin JJ, Logigian EL, Finkel MF, Pearl RA. Practice parameters for the diagnosis of patients with nervous system Lyme borreliosis (Lyme disease). Neurology 1996;46:619-27
5. Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med 1990;323:1438-44
6. Halperin JJ, Little BW, Coyle PK, Dattwyler RJ. Lyme disease: Cause of a treatable peripheral neuropathy. Neurology 1987; 37:1700-6
7. Ackermann R, Rehse-Kupper B, Gollmar E, Schmidt R. Chronic neurologic manifestations of erythema migrans borreliosis. Ann NY Acad Sci 1988;539:16-23
8. Halperin J, Luft BJ, Volkman DJ, Dattwyler RJ. Lyme neuroborreliosis. Peripheral nervous system manifestations. Brain 1990; 113:1207-21
9. Pachner AR. Early disseminated Lyme disease: Lyme meningitis. Am J Med 1995;98(Suppl 4A) 30S-43S
10. Gerber MA, Shapiro ED, Burke GS, Parcells VJ, Bell GL. Lyme disease in children in southeastern Connecticut. N Engl J Med 1996;335:1220-4
11. Steere AC, Malawista SE, Newman JH, et al. Antibiotic therapy in Lyme disease. Ann Intern Med 1980;93:1-8
12. Reik L, Steere AC, Bartenhagen NH, Shope RE, Malawista SE. Neurologic abnormalities of Lyme disease Medicine 1979;58: 281-94
13. Steere AC, Schoen RT, Taylor E. The clinical evolution of Lyme arthritis. Ann Intern Med 1987;107:725-31
14. Asbrink E, Olsson I, Hovmark A. Erythema chronicum migrans afzelius in Sweden A study on 231 patients. Zentralbl Bakteriol Mikrobiol Hyg A 1986;263:229-36
15. Szer IS, Taylor E, Steere AC. The long-term course of Lyme arthritis in children. N Engl J Med 1991;325:159-63
16. Barbour AG Isolation and cultivation of Lyme disease spirochetes. Yale J Biol Med 1984;57:521-5
17. Berger BW, Johnson JC, Kodner C, Coleman L. Cultivation of Borrelia burgdorferi from erythema migrans lesions and perilesional skin. J Clin Microbiol 1992;30:359-61
18. Karlsson M, Hovind-Hougen K, Svenungsson B, Stiernstedt G. Cultivation and characterization of spirochetes from cerebrospinal fluid of patients with Lyme borreliosis. J Clin Microbiol 1990;28:473-9
19. Halperin J. Neuroborreliosis. Am J Med 1995;98(Suppl 4A):52S-59S
20. Nocton JJ, Bloom BJ, Rutledge BJ, et al. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in cerebrospinal fluid in Lyme neuroborreliosis. J Infect Dis 1996; 174:623-7
21. Tauber MG, Sande MA. General principles of therapy of pyogenic meningitis Infect Dis Clin NA 1990;4:661-76
22. Pachner AR, Braswell ST, Delaney E, Amemiya K, Major E. A rabbit model of Lyme neuroborreliosis: Characterization by PCR, serology, and sequencing of the OspA gene from the brain. Neurology 1994;44:1938-43
23. Pachner AR, Delaney E, O'Neill T, Major E. Inoculation of nonhuman primates with the N40 strain of Borrelia burgdorferi leads to a model of Lyme neuroborreliosis faithful to the human disease. Neurology 1995;45:165-72
24. Scheld WM. Drug delivery to the central nervous system: General principles and relevance to therapy of infections of the central nervous system. Rev Infect Dis 1989;11(Suppl 7):S1669-S1690
25. Kramer PW, Griffith RS, Campbell RL. Antibiotic penetration of the brain. A comparative study. J Neurosurg 1969;31:295-302
26. Dattwyler RJ, Volkman DJ, Conaty SM, Plotkin SP, Luft BJ. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet 1990;336:1404-6
27. Fishman RA. Blood-brain and CSF barriers to penicillin and related organic acids Arch Neurol 1966;15:113-24
28. Gibaldi M, Schwartz MA. Apparent effect of probenecid on the distribution of penicillin in man. Clin Pharmacol Ther 1968; 9:345-9
29. Steere AC, Levin RE, Molloy PJ. et al. Treatment of Lyme arthritis. Arthritis Rheum 1994;37:878-88
30. Goodman JL, Bradley JF, Ross AE, et al. Bloodstream invasion in early Lyme disease: Results from a prospective, controlled, blinded study using the polymerase chain reaction. Am J Med 1995;99:6-12
31. Kuiper H, de Jongh BM, van Dam AP, et al. Evaluation of central nervous system involvement in Lyme borreliosis patients with a solitary erythema migrans lesion. Eur J Clin Microbiol Infect Dis 1994;13:379-87
32. Garcia-Monco JC, Villar BF, Alen JC, Benach JL. Borrelia burgdorferi in the central nervous system, experimental and clinical evidence for early invasion. J Infect Dis 1990;161: 187-93
33. Luft BJ, Steinman CR, Neimark HC, et al. Invasion of the central nervous system by Borrelia burgdorferi in acute disseminated infection. JAMA 1992;267:1364-7
34. Dattwyler RJ, Luft BJ, Maladorno D, et al. Treatment of early disseminated Lyme disease - ceftriaxone vs doxycycline VII International Congress on Lyme Borreliosis. San Francisco, June 1996
35. Dotevall L, Alestig K, Hanner P, Norkrans G, Hagberg L. The use of doxycycline in nervous systems Borrelia burgdorferi infection. Scand J Infect Dis 1988;53 (Suppl):74-9
36. Barza M, Brown RB, Shanks C, Gamble C, Weinstein L. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs. Antimicrob Agents Chemother 1975;8:713-30
37. Karlsson M, Hammers-Berggren S, Lindquist L, Stiernstedt G, Svenungsson B. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme borreliosis. Neurology 1994;44:1203-7
38. Kohlhepp W, Oschmann P, Mertens HG. Treatment of Lyme borreliosis. Randomized comparison of doxycycline and penicillin G. J Neurol 1989;236:464-9
39. Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992;117:273-80
40. Kruger H, Kohlhepp W, Konig S. Follow-up of antibiotically treated and untreated neuroborreliosis. Acta Neurol Scand 1990;82:59-67
41. Pfister HW, Einhaupl KM, Franz P, Garner C. Corticosteroids for radicular pain in Bannwarth's syndrome. A double-blind, randomized, placebo-controlled trial. Ann NY Acad Sci 1988; 539:485-7
42. Steere AC, Pachner AR, Malawista SE. Neurologic abnormalities of Lyme disease: Successful treatment with high dose intravenous penicillin. Ann Intern Med 1983;99:767-72
43. Kristoferitsch W. Neuropathien bei Lyme-borreliose. Berlin: Springer-Verlag, 1989
44. Clark JR, Carlson RD, Sasaki CT, Pachner AR, Steere AC. Facial paralysis in Lyme disease. Laryngoscope 1985;95:1341-5
45. Pfister HW, Einhaupl KM, Garner C, Heberl R. Corticosteroids versus penicillin in the treatment of meningoradiculitis of Bannwarth (Bannwarth's syndrome). J Neurol (Suppl)1985;231: 293
46. Pfister H-W, Preac-Mursic V, Wilske B, Schielke E, Sorgel F, Einhaupl KM. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J Infect Dis 1991;163: 311-8
47. Rohacova H, Hancil J, Hulinska D, Mailer H, Havlik J. Ceftriaxone in the treatment of Lyme neuroborreliosis. Infection 1996; 24:90-2
48. Pfister H-W, Preac-Mursic V, Wilske B, Einhaupl KM Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis A prospective randomized study. Arch Neurol 1989;46:1190-7
49. Wormser GP Treatment of Borrelia burgdorferi infection. Lab Med 1990;21:316-21
50. Rahn DW, Malawista SE. Lyme disease: Recommendations for diagnosis and treatment. Ann Intern Med 1991;114:472-81
51. Sigal LH. Current recommendations for the treatment of Lyme disease Drugs 1992;43:683-99
52. Weber K, Pfister H-W. Clinical management of Lyme borreliosis. Lancet 1994;343:1017-20
53. Luft BJ, Gorevic PD, Halperin JJ, Volkman DJ, Dattwyler RJ. A perspective on the treatment of Lyme borreliosis. Rev Infect Dis 1989;11(Suppl 6):1518-25
54. Anonymous. Treatment of Lyme disease. Med Lett 1992;34:95-7
55. Kohler J, Schneider H, Vogt A. High-dose intravenous penicillin G does not prevent further progression in early neurological manifestation of Lyme borreliosis. Infection 1989;17:216-7
56. Pachner AR, Duray P, Steere AC Central nervous system manifestations of Lyme disease. Arch Neurol 1989;46:790-5
57. Bingham PM, Galetta SL, Athreya B, Sladky J. Neurological manifestations in children with Lyme disease. Pediatrics 1995; 96:1053-6
58. Mullegger RR, Millner MM, Stanek G, Spork KD, Penicillin G sodium and ceftriaxone in the treatment of neuroborreliosis in children - A prospective study. Infection 1991;19:279-83
59. Krbkova L, Stanek G. Therapy of Lyme borreliosis in children. Infection 1996;24:170-7
60. Logigian EL, Steere AC. Clinical and electrophysiologic findings in chronic neuropathy of Lyme disease. Neurology 1992;42: 303-11
61. Hassler D, Zoller L, Haude M, Hufnagel HD, Heinrich F, Sonntag HG. Cefotaxime versus penicillin in the late stage of Lyme disease - Prospective, randomized therapeutic study. Infection 1990;18:16-20
62. Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis - Randomized comparison of ceftriaxone and penicillin. Lancet 1988;1:1191-4
63. Anonymous. Drugs for sexually transmitted diseases Med Lett 1994;36:1-6
64. Johnson RC, Kodner C, Russell M. In vitro and in vivo susceptibility of the Lyme disease spirochete, Borrelia burgdorferi, to four antimicrobial agents. Antimicrob Agents Chemother 1987; 31:164-7
65. Mursic VP, Wilskc B, Schierz G, Holmburger M, Suss E. In vitro and in vivo susceptibility of Borrelia burgdorferi. Eur J Clin Microbiol 1987;6:424-6
66. Moody KD, Adams RL, Barthold SW. Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice. Antimicrob Agents Chemother 1994;381:1567-72
67. Malawista SE, Barthold SW, Persing DH. Fate of Borrelia burgdorferi DNA in tissues of infected mice after antibiotic treatment. J Infect Dis 1994;170:1312-6
68. Dattwyler RJ, Luft BJ, Maladorno D, et al. Treatment of late Lyme disease - A comparison of 2 weeks vs 4 weeks of ceftriaxone VII International Congress on Lyme Borreliosis. San Francisco, June, 1996
69. Nadelman RB, Arlen Z, Wormser GP. Life threatening complications of empiric ceftriaxone for "seronegative" Lyme disease. South Med J 1991;84:1263-5
70. Ettestad PJ, Campbell GL, Webel SF, et al. Biliary complications in the treatment of unsubstantiated Lyme disease. J Infect Dis 1995;171:356-61
71. Noordhoek GT, Wolters EC, deJonge MEJ, VanEmbden JDA. Detection by polymerase chain reaction of Treponema pallidum DNA in cerebrospinal fluid from neurosyphilis patients before and after antibiotic treatment J Clin Microbiol 1991;29: 1776-84
72. Johnson RC, Kodner C, Russell M. Active immunization of hamsters against experimental infection with Borrelia burgdorferi. Infect Immun 1986;54:897-8
73. Aberer E, Brunner C, Suchanek G, et al. Molecular mimicry and Lyme borreliosis: A shared antigenic determinant between Borrelia burgdorferi and human tissue. Ann Neurol 1989;26:732-7
74. Lim LCL, England DM, DuChateau BK, et al. Development of destructive arthritis in vaccinated hamsters challenged with Borrelia burgdorferi. Infect Immun 1994;62:2825-33
75. Wormser GP. Prospects for a vaccine to prevent Lyme disease in humans. Clin Infect Dis 1995;21:1267-74
76. Fikrig E, Barthold SW, Kantor FS, Flavell RA. Long-term protection of mice from Lyme disease by vaccination with OspA. Infect Immun 1992;60:773-7
77. Schaible UE, Wallich R, Kramer MD, et al. Immune sera to individual Borrelia burgdorferi isolates or recombinant OspA thereof protect SCID mice against infection with homologous strains but only partially, or not at all against those of different OspA/OspB genotype. Vaccine 1993;11:1049-54
78. Sears JE, Fikrig E, Nakagawa TY, et al. Molecular mapping of OspA mediated immunity against Borrelia burgdorferi, the agent of Lyme disease J Immunol 1991;147:1995-2000
79. Sadziene A, Thompson PA, Barbour AG. In vitro inhibition of Borrelia burgdorferi growth by antibodies. J Infect Dis 1993; 167:165-72
80. Montgomery RR, Nathanson MH, Malawista SE. Fc and non-Fc mediated phagocytosis of Borrelia burgdorferi by macrophages. J Infect Dis 1994;170:890-3
81. Chang Y-F, Appel MJG, Jacobson RH, et al. Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi. Infect Immun 1995;63:3543-9
82. Padilla ML, Callister SM, Schell RF, et al. Characterization of the protective borreliacidal antibody response in humans and hamsters after vaccination with a Borrelia burgdorferi outer surface protein A vaccine. J Infect Dis 1996;174:739-46
83. Preac-Mursic V, Wilske B, Patsouris E, et al. Active immunizations with pC protein of Borrelia burgdorfen protects gerbils against B. burgdorfen infection. Infection 1992;20:342-9
84. Fikrig E, Telford SR III, Barthold SW, Kantor FS, Spielman A, Flavell RA. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice. Proc Natl Acad Sci USA 1992;89:5418-21
85. Piesman J, Mather TN, Sinsky RJ, Spielman A. Duration of tick attachment and Borrelia burgdorferi transmission. J Clin Microbiol 1987;25:557-8
86. deSilva AM, Telford SR III, Brunet LR, Barthold SW, Fikrig E. Borrelia burgdorferi OspA is an arthropod specific transmission blocking Lyme disease vaccine. J Exp Med 1996;183: 271-5
87. Keller D, Kostcr FT, Marks DH, Hosbach P, Erdite LF, Mays JP. Safety and immunogenicity of a recombinant outer surface protein A Lyme vaccine. JAMA 1994;271:1764-8
88. Schoen RT, Meurice F, Brunet CM, et al. Safety and immunogenicity of an outer surface protein A vaccine in subjects with previous Lyme disease. J Infect Dis 1995;172:1324-9
89. Craft JE, Fischer DK, Shimamoto GT, Steere AC. Antigens of Borrelia burgdorferi recognized during Lyme disease: Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness. J Clin Invest 1986;78:934-9
90. Kalish RA, Leong JM, Steere AC. Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect Immun 1993;61:2774-9
91. Kamradt T, Lengl-Janben B, Strauss AF, Bansal G, Steere AC. Dominant recognition of a Borrelia burgdorferi outer surface protein A protein by T helper cells in patients with treatment resistant Lyme arthritis. Infect Immun 1996;64:1284-9